Hee Kyung Ahn
Oncology Hee Kyung Ahn Favorite Doctor
  • SpecialtyHead and neck cancer, Breast cancer, Lung cancer
  • Site Naver
      You Tube
Appointment
Schedule
의료진 진료일정
Week M T W T F S
AM     Present Present    
PM         Present  
Clinical Interests

Head and neck cancer
Lung cancer
Breast cancer
Cancer of unknow origin and other solid cancers

Education
Education
Sungkyunkwan University School of Medicine, M.S.
Sungkyunkwan University School of Medicine, M.D.
Career
Career
Gachon University Gil Medical Center, Associate Professor
Gachon University Gil Medical Center, Asistant Professor
Gachon University Gil Medical Center, Clinical Asistant Professor
Samsung Medical Center, Clinical Instructor
Samsung Medical Center, Resident
Samsung Medical Center, Intern
More
Community
Community
More
Training
Training
2011 Visiting fellow, Roswell Park Cancer Institute, NY, USA
2009.9 Visiting resident, Dana-Farber Cancer Institute, MA, USA
License
License
License of Medical Doctor
Internal Medicine, Specialist
Hematology Oncology, Specialist
Hee Kyung Ahn
Paper
Paper
2016 Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med. 2016 Apr 20. [Epub ahead of print]
2016 Ahn HK, Hwang IC, Lee JS, Sym SJ, Cho EK, Shin DB. Neutrophil-Lymphocyte Ratio Predicts Survival in Terminal Cancer Patients. J Palliat Med. 2016 Feb 17.Epub ahead of print.
2015 Hyun SH, Ahn HK, Ahn MJ, Ahn YC, Kim J, Shim YM, Choi JY. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. AJR Am J Roentgenol. 2015;Sep;205(3):623-628.
2015 Kim SW, Hwang IC, Ahn HK, Kyung SY, Ahn HY. Medical Manuscript: Serum Total Testosterone as a Prognostic Indicator in Male Patients With Terminal Cancer. Am J Hosp Palliat Care. 2015 Feb 23. Epub ahead of print.
2014 Ahn HK, Shin JW, Ahn HY, Park CY, Lee NW, Lee JK, Hwang IC. Metabolic components and recurrence in early-stage cervical cancer. Tumour Biol. 2014 Nov 15 Epub ahead of print
2014 Woo HS, Ahn HK, Lee HY, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Epidermal growth factor receptor exon 20 mutations in non-small cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Investigational New Drugs. 2014 Aug 23 Epub ahead of print.
2014 Ahn HK, Jung M, Syn SJ, Shin DB, Kang SM, Kyung SY, Park JW, Jeong SH, Cho EK. A Phase II Trial of Cremorphor EL-free Paclitaxel (Genexol-PM) and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer. Cancer Chemotherapy Pharmacology. 2014 Aug;74(2):277-82.
2014 Ahn HK, Jung M, Ha SY, Lee JI, Park I, Kim YS, Hong J, Sym SJ, Park J, Shin DB, Lee JH, Cho EK. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. Tumour Biology. 2014 Jun;35(6):5735-40.
2013 Ahn HK, Choi JY, Kim KM, Kim H, Choi SH, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. British Journal of Cancer. 2013 Sep 17; 109(6):1414-9
2013 Ahn HK, Kim SJ, Hwang DW, Ko YH, Tang T, Lim ST, Kim WS. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Investigational New Drugs. 2013 Apr;31(2):469-72.
2013 Ahn HK, Park YH, Lee SJ, Park S, Maeng CH, Park W, Choi DH, Hur SJ, Ahn JS, Im YH. Clinical implication of time to brain metastasis (TTBM) according to breast cancer subtypes. SpringerPlus. 2013 Mar 28;2(1):136. Print 2013 Dec.
2013 Ahn HK, Choi YL, Han JH, Ahn YC, Kim K, Kim J, Shim YM, Um SW, Kim H, Kwon OJ, Sum JM, Ahn JS, Park K, Ahn MJ. Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery. Lung Cancer. 2013 Mar; 79(3):300-6.
2013 Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, Lee MJ, Ha SY, Han JH, Sun JM, Ahn JS, Ahn MJ, Park K. Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small cell lung cancer. Journal of Thoracic Oncology. 2013 Feb;8(2):250-3.
2013 Lee HY, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, Ahn JS, Park K, Choi YL, Ahn JM. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small cell lung cancer. Lung Cancer. 2013 Jan;79(1):40-5.
2013 Kim HJ, Ahn HK, Jung CW*, Moon JH, Park CH, Lee KO, Kim SH, Kim YK, Kim HJ, Sohn SK, Kim SH, Lee WS, Kim KH, Mun YC, Kim W Park J, Min WS, Kim HJ, Kim DH. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Annals of Hematology. 2013 Jan; 92(2):163-71.
2012 Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, Kim WS. Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Annals of Oncology. 2012 Oct;23(10):2703-7.
2012 Ahn HK, Lee S, Park YH, Sohn JH, Jo JC, Ahn JH, Jung KH, Park S, Cho EY, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kim SB, Im YH. Prediction of outcomes for patients with brain parenchymal metastases from breast cancer(BC): a new BC-specific prognostic model and a nomogram. Neuro-oncology. 2012 Aug;14(8):1105-13.
2012 Ahn HK, Lee S, Sun JM, Lee J, Park SH, Park JO, Park YS, Kang WK, Lim HY. Sequential Therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma. Investigational New Drugs. 2012 Aug;30(4):1768-72.
2012 Ahn HK, Han B, Lee SJ, Lim T, Sun JM, Ahn JS, Ahn MJ, Park K. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. Lung Cancer. 2012 May;76(2):253-4.
2012 Ahn HK, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, Kim DH. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome, and associates with high functional multidrug resistance (MDR) activity. American Journal of Hematology. 2012 Jan;87(1):37-41.
2011 Ahn HK, Jang J, Lee J, Park SH, Park JO, Park YS, Lim HY, Kim KM, Kang WK. P21-activated kinase 4 overexpression in metastatic gastric cancer patients. Translational Oncology. 2011 Dec;4(6):345-9.
2011 Lee S, Ahn HK, Park YH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat. 2011 Oct;129(3):809-17.
2011 Ahn HK, Uhm JE, Lee J, Lim DH, Seo SW, Sung KS, Lee SJ, Lee DJ, Baek KK, Kim WS, Park JO. Analysis of prognostic factors of pediatric-type sarcomas in adult patients. Oncology. 2011 May 23;80(1-2):21-28
2011 Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Cancer. 2011 Jan 1;117(1):143-51.
2010 Ahn HK, Kim SJ, Yun J, Yi JH, Kim JH, Won YW, Kim K, Ko YH, Kim WS. Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. Int J Hematol. 2010 Apr;91(3):456-63.
2009 Ahn HK, Song HJ, Lee SJ, Yi JH, Kim SA, Lee J, Kim WS. A case of membranous glomerulonephritis associated with apocrine carcinoma. Korean J Med. 2009:77(suppl 2):415-419. [Korean]
More